Drug Cardsn

Front 1

cimetidine aka

Back 1

tagamet

Front 2

cimetidine class

Back 2

H2 antagonist

Front 3

cimetidine iv dose

Back 3

300mg

Front 4

cimetidine clinical use

Back 4

decrease aspiration pneumonitis, treat ulcers, GERD

Front 5

cimetidine onset and duration

Back 5

1 hour onset, 4-8 hour duration

Front 6

cimetidine MOA

Back 6

competitively inhibits histamine by binding to H2 receptors, thereby reducing gastric acid output

Front 7

cimetidine adverse reactions

Back 7

headache, diarrhea, BRONCHOSPASM, heart block, hoTN, arrhythmias, cardic arrest, bradycardia

Front 8

cimetidine interactions

Back 8

binds to CYP450, slowing drug metabolism (warfarin, phenytoin, etc)

Front 9

cimetidine contraindications

Back 9

renal disease

Front 10

cimetidine metabolism

Back 10

hepatic & renal

Front 11

cimetidine's effect on muscle relaxants

Back 11

prolongs action of NDMRs and DRMs

Front 12

benadryl class

Back 12

H1 blocker

Front 13

benadryl dose

Back 13

10-50mg IV (0.5-1.5mg/kg)

Front 14

benadryl onset and duration

Back 14

onset 1-3 minutes, duration 3-6 hours

Front 15

benadryl clinical use

Back 15

suppression of allergies, vertigo, N/V, sedation

Front 16

benadryl MOA

Back 16

competitively inhibits H1 receptors (does not effectively tx bronchospasm)

Front 17

benadryl adverse reactions

Back 17

hoTN, tachycardia, dizziness, urinary retention, seizures, dry mouth, anticholinergic effects, sedation

Front 18

benadryl interactions

Back 18

potentiates other CNS depressants, MAOIs prolong

Front 19

benadryl metabolism

Back 19

hepatic

Front 20

dolasetron aka

Back 20

anzemet

Front 21

anzemet class

Back 21

5HT3 receptor antagonist

Front 22

anzemet dose

Back 22

12.5mg (0.2mg/kg)

Front 23

anzemet onset and duration

Back 23

onset < 30 minutes (must be reduced to active metabolite before it can work), duration 24 hours

Front 24

anzemet clinical use

Back 24

prevention and tx of PONV

Front 25

anzemet MOA

Back 25

selectively blocks peripheral and central 5HT3 receptors

Front 26

anzemet adverse reactions

Back 26

prolonged QT interval

Front 27

anzemet interactions

Back 27

caution with diuretic and antiarrhythmic therapy

Front 28

contraindications to anzement

Back 28

prolonged QT syndrome

Front 29

anzemet metabolism

Back 29

hepatic

Front 30

granisitron aka

Back 30

kytril

Front 31

kytril classification

Back 31

selective 5HT3 receptor antagonist

Front 32

kytril dose

Back 32

1mg IV (0.014 mg/kg)

Front 33

kytril onset and duration

Back 33

onset < 30 minutes, duration up to 8 hours

Front 34

kytril use

Back 34

prevention and treatment of PONV

Front 35

kytril MOA

Back 35

selectively antagonizes 5HT3 receptors peripherally and centrally

Front 36

kytril adverse effects

Back 36

headache, prolonged QT

Front 37

kytril interactions

Back 37

caution with diuretic and antiarrhythmic therapy

Front 38

contraindications to kytril

Back 38

prolonged QT

Front 39

kytril metabolism

Back 39

hepatic

Front 40

ondanestron aka

Back 40

zofran

Front 41

zofran classification

Back 41

selective 5HT3 receptor antagonist

Front 42

zofran dose

Back 42

4mg (0.4-0.5mg/kg)

Front 43

zofran onset and duration

Back 43

onset < 30 minutes, duration 3-6 hours

Front 44

zofran clinical use

Back 44

prevention and treatment of PONV

Front 45

zofran MOA

Back 45

selectively antagonizes peripheral and central 5HT3 receptors

Front 46

zofran adverse reactions

Back 46

headache, bradycardia, prolonged QT

Front 47

zofran interactions

Back 47

caution with diuretics and antiarrhythmic therapy

Front 48

zofran contraindications

Back 48

decrease dose in liver disease

Front 49

zofran metabolism

Back 49

hepatic

Front 50

ketoralac aka

Back 50

toradol

Front 51

ketoralac class

Back 51

NSAID

Front 52

ketoralac dose

Back 52

30-60mg

Front 53

ketoralac onset and duration

Back 53

onset 10 minutes, duration 6-8 hours

Front 54

ketoralac clinical use

Back 54

analgesia, antipyretic, anti-inflammatory

Front 55

ketoralac MOA

Back 55

COX 1 and 2 inhibition, prosteglandin inhibition, doesn't cross BBB

Front 56

ketoralac adverse reactions

Back 56

inhibits platelet aggregation and prolongs bleeding, renal toxicity, GI ulcers

Front 57

ketoralac interactions

Back 57

avoid use with ASA and other NSAIDS

Front 58

ketoralac contraindications

Back 58

renal failure, recent GIB, not for use in pregnancy

Front 59

ketoralac metabolism

Back 59

hepatically metabolized and renally excreted

Front 60

methylene blue dose

Back 60

1-2mg/kg

Front 61

methylene blue use

Back 61

treatment of methemoglobinemia, diagnostic dye

Front 62

methylene blue adverse reactions

Back 62

N/V, ha, transient decrease in pulse ox, anemia with G6PD deficiency

Front 63

methylene blue contraindications

Back 63

G6PD deficiency, renal insufficiency

Front 64

methylene blue metabolism

Back 64

hepatic (CYP 450)

Front 65

metaclopramide aka

Back 65

reglan

Front 66

reglan class

Back 66

dopamine antagonist

Front 67

reglan dose

Back 67

10-20mg (0.25mg/kg)

Front 68

reglan onset and duration

Back 68

onset 1-3 minutes, duration 1-2 hours

Front 69

reglan clinical use

Back 69

PONV prophylaxis, increase gastric motility and decrease gastric volume, GERD, gastroparasis

Front 70

reglan MOA

Back 70

antagonizes dopamine receptors in the CTZ, increasing GI motility and accelerating emptying, increases LES tone

Front 71

reglan adverse reactions

Back 71

sedation, dry mouth, depression, EP symptoms, cardiac dysrhythmias, abd cramps, may inhibit plasma cholinesterase

Front 72

reglan interactions

Back 72

additive CNS depression with other CNS depressants

Front 73

reglan contraindications

Back 73

GI obs, pheo, HTN crisis, parkinsons, opposed by atropine/glyco

Front 74

reglan metabolism

Back 74

hepatic, 85% excreted unchanged in urine

Front 75

reglan dose adjustment in pts with

Back 75

renal dysfunction

Front 76

midazolam aka

Back 76

versed

Front 77

preop midazolam dose

Back 77

0.5-5mg (0.02-0.1mg/kg)

Front 78

midazolam onset

Back 78

1 minute

Front 79

midazolam duration

Back 79

2 hours (short acting)

Front 80

midazolam half life

Back 80

2-4 hours

Front 81

midazolam MOA

Back 81

binds to GABA, opens Cl channels, and hyperpolarizes receptor

Front 82

midazolam interactions

Back 82

synergistic with opioids and propofol, enhances resp dep and sedation

Front 83

midazolam se

Back 83

drowsiness, decreased CBF/CMRO2/ICP

Front 84

midazolam metabolism

Back 84

hepatic

Front 85

midazolam induction dose

Back 85

0.15-0.3mg/kg

Front 86

midazolam CI

Back 86

hepatic or renal impairment (active metabolite)

Front 87

lorazepam aka

Back 87

ativan

Front 88

preop ativan dose

Back 88

0.5-4mg IV

Front 89

ativan induction dose

Back 89

0.1-0.25mg/kg

Front 90

ativan onset

Back 90

1 minute

Front 91

ativan duration

Back 91

6-8hours

Front 92

ativan half life

Back 92

10-20 hours

Front 93

ativan MOA

Back 93

binds to GABA, opens Cl channels, hyperpolarizes

Front 94

ativan SE

Back 94

drowsiness, fatigue, decreased BP/increased HR

Front 95

ativan interactions

Back 95

synergistic effect with opioids and propofol, enhancing resp dep and sedation

Front 96

benzodiazepine CI

Back 96

pregnancy, glaucoma, caution in hepatic and renal disease

Front 97

ativan metabolism

Back 97

hepatic

Front 98

diazepam aka

Back 98

valium

Front 99

valium preop dose

Back 99

2-10mg (0.05-0.2mg/kg)

Front 100

valium induction dose

Back 100

0.3-0.6mg/kg

Front 101

valium onset

Back 101

1 minute

Front 102

valium duration

Back 102

6-8 hours

Front 103

valium half life

Back 103

20-40 hours

Front 104

valium metabolism

Back 104

hepatic

Front 105

valium metabolism delayed by

Back 105

cimetidine

Front 106

etomidate aka

Back 106

amidate

Front 107

etomidate classification

Back 107

carboxylated imidazole

Front 108

etomidate onset/duration

Back 108

30 seconds/3-8 minutes

Front 109

etomidate MOA

Back 109

binds to GABA, allows Cl influx, hyperpolarization

Front 110

etomidate SE

Back 110

myoclonia, adrenal suppression (11 b hydroxylase), injection pain, PONV, decreased ICP/CBF/CMRO2/IOP

Front 111

etomidate CI

Back 111

seizure hx, porphyria

Front 112

etomidate metabolism

Back 112

hepatic and plasma esterases (ester hydrolysis)

Front 113

etomidate supplied

Back 113

2mg/ml

Front 114

ketamine aka

Back 114

ketalar

Front 115

ketamine class

Back 115

phencyclidine

Front 116

ketamine dose

Back 116

1-2mg/kg

Front 117

ketamine onset/duration

Back 117

30 sec/3-5 minutes

Front 118

ketamine moa

Back 118

non competitive antagonist at NMDA receptor, block glutamate

Front 119

ketamine CI

Back 119

psych disorders, increased ICP/IOP, HTN, CAD, glaucoma

Front 120

metabolism ketamine

Back 120

hepatic metabolism, renal excretion

Front 121

ketamine supplied

Back 121

10mg/ml, 5mg/ml

Front 122

propofol onset/duration

Back 122

30sec/3-10 minutes

Front 123

propofol moa

Back 123

binds to GABA, allows Cl influx, hyperpolarizes

Front 124

propofol se

Back 124

cardiac depression

Front 125

propofol CI

Back 125

soy, peanut, egg allergy

Front 126

propofol supplied

Back 126

10mg/ml

Front 127

thiopental aka

Back 127

pentothal

Front 128

pentothal classification

Back 128

short acting barbiturate

Front 129

pentothal induction dose

Back 129

3-5mg/kg

Front 130

pentothal onset/duration/half life

Back 130

30 sec/5-10 minutes/10-12 hours

Front 131

pentothal active metabolite

Back 131

phenobarbital

Front 132

barbiturate MOA

Back 132

binds to GABA, allows Cl influx, hyperpolarizes

Front 133

pentothal SE

Back 133

histamine release, liver enzyme induction

Front 134

barbiturate SE

Back 134

decrease ICP/CMRO2/IOP/CBF, hypotension, tachycardia, anticonvulsant

Front 135

barbiturate CI

Back 135

porphyria

Front 136

pentothal CI

Back 136

porphyria, reactive airway diseases

Front 137

pentothal supplied

Back 137

20mg/ml

Front 138

methohexital, aka

Back 138

brevital

Front 139

brevital dose

Back 139

1-2mg/kg

Front 140

brevital onset/duration

Back 140

immediate/1-20 minutes

Front 141

brevital supplied

Back 141

10mg/ml

Front 142

brevital classification

Back 142

ultra short acting barb

Front 143

barbiturate metabolism

Back 143

hepatic